The abbreviations used are: HES-1, Hairy and Enhancer-of-split-1; Runx2, Runt related transcription factor 2; Dll, Delta Like Ligand; AP-1, Activating Protein-1; ERK, Extracellular signal-regulated kinase; OSE-2, osteoblastspecific element 2.
INTRODUCTION
Prostate carcinoma most commonly metastasizes to the lymph nodes and to bone with a 70-80 % frequency as determined by autopsy studies. A unique characteristic of skeletal metastases of human prostate cancer is their ability to induce osteoblastic lesions, characterized by new woven bone formation and variable degrees of osteoclastic bone resorption (1) . It has been proposed that factors produced by prostate cells, both normal and neoplastic, have the potential to stimulate new bone formation by effects on both osteoblasts and osteoclasts. Included in this group are parathyroid hormone related peptide (PTHrP) (2) , transforming growth factor-β (TGF-β) (3), urokinase-type plasminogen activator (4), bone morphogenetic proteins (BMP) (5, 6 ) and endothelin-1 (7) . The production of these factors by prostate cancer cells, accompanied by the release of growth factors during osteolysis, is proposed to result in stimulating new woven bone formation by increasing the differentiation of osteoblasts in the bone.
Interestingly, there is increasing evidence that prostate cancer bone metastases express genes and proteins typically associated with osteoblasts, including RANK ligand (RANKL), osteoprotegerin (OPG) (8) , sialoproteins, osteopontin (9) , Runt related transcription factor 2 (Runx2) (10) and osteocalcin (11) . This phenomenon has been attributed to a "unique" ability of prostate cancer cells to acquire "osteoblast-like properties" upon metastasizing to the bone micro-environment thus enabling them to grow and thrive in this highly restrictive environment (10, 11) .
Cell fate determination, mediated by local cell-cell contact, plays a critical role during development of multicellular organisms. The Notch signaling pathway is an evolutionarily conserved mechanism utilized by organisms, ranging from worms through man, involved in fate determination of various cell lineages. Notch belongs to the family of epidermal growth factor (EGF)-like homeotic genes, 5 "Jagged" (Jagged -1 and -2). Activation of Notch upon ligand binding is accompanied by proteolytic processing by γ-secretase that releases the intracellular domain of Notch (NICD) from the membrane.
The NICD then translocates into the nucleus and associates with the CSL [CBF-1 (RBP-Jκ)/Su(H)/Lag-1] family of DNA-binding proteins to form a transcriptional activator (15) . Most of the Notch target genes encode transcription regulators, which in turn, modulate cell fate by affecting the function of tissuespecific basic helix-loop-helix transcription factors or through other molecular targets, such as Activating protein-1 (AP-1) (16), NF-κB (17) and most importantly, HES-1 (18) . Since Notch ligands are predominantly cell membrane associated, Notch signaling is thought to mediate interactions between contiguous cells at many sites in the human body, including bone, where it has been shown recently that Notch1 activation by Dll1 stimulates the differentiation of osteoblasts (19) .
Osteoblasts, the bone-forming cells, are derived from mesenchymal stem cells after osteogenic differentiation. Under in vitro osteogenic conditions, isolated human mesenchymal stem cells (hMSC) form mineralized aggregates or nodules and increase their expression of alkaline phosphatase (ALP) and osteocalcin (OC), which are important markers of osteoblast differentiation (20) . Many of the osteoblastrelated genes are modulated by Runx2 binding to a specific DNA element in the regulatory region of these target genes. Runx2 is an essential transcription factor for the differentiation of osteoblasts from mesenchymal precursors and the regulation of bone matrix deposition by differentiated osteoblasts (21) .
This suggests that Runx2 regulates osteoblast gene expression and function at multiple levels. Recent studies have demonstrated that prostate cancer cells, similar to mature osteoblasts, are capable of expressing and secreting osteocalcin upon metastasizing to bone (11) . In addition, it has been shown that the osteoblastic C4-2B prostate cancer cell line (LNCaP derivative cell line) (22) has an increased expression of Runx2 (10) while the osteolytic PC3 cell line expresses transcriptionally active Cbaf1 as shown by its ability to bind to OSE2 on the osteocalcin promoter (11) . This suggests that Runx2 expression/activity could play a role in the modulation of gene expression in prostate cancer metastases.
Interestingly, HES-1 (a down-stream target of Notch signaling) can physically interact with Runx2 and potentiate its mediated transactivation in transfected cells (18) . Based on this, we hypothesize that the by guest on September 16, 2017 http://www.jbc.org/ Downloaded from 6 activation of Notch in prostate cancer metastases in the bone micro-environment leads to a cascade of signaling events which ultimately results in a unique pattern of gene expression similar to that seen in mature osteoblasts.
The aim of the present study was to examine the role of the Notch signaling pathway in the unique osteomimetic properties of prostate cancer bone metastases. We report that osteoblastic prostate cancer cell lines (C4-2B and MDA PCa2b) specifically express Notch1, and the Notch ligand, Dll1, is expressed only in the C4-2B cell line. This expression pattern of Notch receptor and ligand leads to the expression of HES-1 transcription factor independent of ERK activation. Furthermore, we demonstrate that in vitro osteogenic induction of prostate cancer cells increases ERK phosphorylation and Runx2 expression and activation, independent of Notch activation. Finally, we demonstrate that Notch signaling and ERK activation in skeletal prostate cancer metastases is critical for Runx2 DNA binding and osteocalcin expression. Taken together, our results suggest that Notch activation plays a critical role in the ability of prostate cancer metastases to acquire "osteoblast-like" properties. 
EXPERIMENTAL PROCEDURES

Cell Culture and Osteoblastic Differentiation
The human prostatic cell lines (Table 1) DU145, LNCaP, and MDA PCa 2b were purchased from the American Type Culture Collection, Manassas, VA. The C4-2B cell line was purchased from UroCor, Inc. Oklahoma City, OK. In addition, we used hMSC provided by the UAB NIH-funded Research Core Center for Musculoskeletal Disease. DU145 and LNCaP were maintained in RPMI 1640 containing 10 % FBS. MDA PCa 2b was maintained in Kaighn's modification of Ham's F12 (F12K) supplemented with 25 ng/ml Cholera toxin, 10 ng/ml Epidermal Growth Factor, 0.005 mM phosphoethanolamine, 100 pg/ml hydrocortisone, 45 nM selenious acid, 0.005 mg/ml insulin and 20 % FBS. The C4-2B cell line was maintained in T medium (80% Dulbecco's modified Eagle's medium (DMEM), 20 % F12 media, 3g/L NaCO 3 , 5µg/ml insulin, 13.6 pg/ml triiodothyronine, 5 µg/ml transferrin, 0.25 µg/ml biotin, 25 µg/ml adenine) supplemented with 5% FBS. The hMSC were maintained in DMEM containing 10 % FBS. All cultures were supplemented with 100 U/L penicillin G and 100 µg/ml streptomycin. For osteogenic induction, regular medium was supplemented with 10 mM β-glycerophosphate and 50 µM ascorbic acid-2-phosphate (23).
RNA extraction and RT-PCR
Total RNA was extracted using the TRIzol method as recommended by the manufacturer (Invitrogen). The yield and purity of RNA was estimated spectrophotometrically using the A 260 /A 280 ratio. The quality of RNA was examined by gel electrophoresis. One microgram of RNA was reverse transcribed using M-MLV reverse transcriptase and the equivalent of 10 ng was used for the PCR reactions. These were carried out in a final volume of 25 µl containing 0. 
Whole Cell Protein Extraction
At the end of the study, cells were washed with chilled phosphate-buffered saline (PBS) and centrifuged at 800g for 5 minutes at 4˚C then resuspended in lysis buffer (50mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and 10% glycerol). A mixture of protease and phosphatase inhibitors consisting of 2mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 1mM EGTA, 10 mM NaF, 1 mM sodium pyrophosphate, 1 mM sodium orthovanadate, and 0.1 mM β-glycerophosphate was added to the lysis buffer. Samples were then centrifuged at 14,000 rpm for 30 minutes at 4˚C and the supernatant protein concentration was measured using the Bio-Rad DC protein assay (25) .
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Western Blot Analysis
Whole cell or nuclear extracts were loaded (30µg/lane) onto an SDS mini-PAGE system.
Following electrophoresis, proteins were transferred to a polyvinylidene difluoride (PVDF) membrane, Immobilon-P, (Millipore Co.) using a Bio-Rad wet transfer system. Protein transfer efficiency and size determination were verified using prestained protein markers. Membranes were then blocked with Blotto B (Santa Cruz Biotechnology) for 1 hour at room temperature and subsequently incubated overnight with antibodies directed against Notch1, ERK, phosphorylated ERK, Runx2 and actin (Santa Cruz Biotechnology). Signals were detected using a horseradish peroxidase-conjugated secondary antibody and an enhanced chemiluminescence detection kit (ECL, Amersham Bioscience).
Calcium Measurement
Cells were lysed with double distilled H 2 O, accompanied by 3 freeze/thaw cycles. Calcium content was measured using a calcium detection kit (Arsenazo III, Sigma-Aldrich Corp, St. Louis, MO).
Nuclear Protein Extraction
C4-2B cells were washed with chilled PBS and centrifuged at 800g for 5 minutes at 4˚C. Nuclei were then isolated by detergent lysis of the cells using an NP40 lysis buffer containing 10 mM Tris, 10 mM NaCl, 3 mM MgCl 2 , 0.5% NP40 and 0.56M sucrose. Nuclei were then treated with a hypotonic solution containing 10 mM HEPES, 1.5mM MgCl 2 and 10 mM KCl followed by a 30-minute incubation at 4˚C in an extraction buffer containing 20 mM HEPES, 20% glycerol, 600 mM KCl, 1.5 mM MgCl 2 and 0.2 mM EDTA. Nuclei were finally centrifuged at 14,000 rpm for 30 minutes at 4˚C and the supernatant protein concentration was measured by the Bio-Rad DC Protein Assay. All solutions in this procedure contained a cocktail of protease and phosphatase inhibitors similar to that used in the whole cell protein extraction.
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Electrophoretic Mobility Shift Assay (EMSA)
Four µg of nuclear extracts were incubated for 20 minutes at room temperature with a 32 P-labeled oligonucleotide containing the human Runx2 consensus sequence. The oligonucleotide sequence which was used as a probe is as follows: 5'-CGCAGCTCCCAACCACATATCCTCT-3' (26) (top strand), derived from the human osteocalcin promoter (-141 to -165), and contains an OSE2 motif (AACCACA) (27) . Oligonucleotide with mutation in the Runx2 binding site was also used to confirm binding specificity. The mutant Runx2 sequence is 5'-CGCAGCTCCCAgaCAC ATATCCTCT-3' (top strand).
The double-stranded Runx2 probe was end labeled using [γ-32 P] ATP and T4 polynucleotide kinase according to standard protocols. DNA-protein complexes were then resolved by 5% native polyacrylamide gels. Gels were dried and exposed to X-ray film at -80 ˚C with an intensifying screen.
For supershift experiment, nuclear extracts (10 µg) were incubated with HES-1 antibody (Santa Cruz) in binding buffer for 45 minutes at room temperature. 32 P-labeled oligonucleotide containing the human Runx2 consensus sequence was then added and the mixture was further incubated for 30 minutes at room temperature.
Immunohistochemistry and Human Tissue Samples
Human bone samples from 4 patients were obtained from the Surgical Pathology Department of the University of Alabama at Birmingham Hospitals and Clinics with the approval of the Institutional Review Board. Tissues were formalin-fixed and decalcified in EDTA before processing on a VIP tissue processor followed by paraffin embedding. Sections were cut at 5 microns for immunostaining. C4-2B cells were cultured on glass coverslips for 4 days and then formalin fixed.
Tissues were deparaffinized and rehydrated, followed by antigen retrieval using 10mM citrate buffer, pH 6. Endogenous peroxidase activity was quenched using 1% hydrogen peroxide. Samples were then blocked for 1 hour in Fc Receptor Blocker (INNOVEX BIOSCIENCES, Richmond, CA.). Anti- 11 followed by incubation with avidin-biotin enzyme reagents. Finally, specimens were incubated in peroxidase substrate for 30 seconds. Tissues were counterstained in Gill's heamatoxylin for 10 seconds, dehydrated, mounted and coversliped. Negative controls were processed alongside the examined tissue, but rabbit IgG was used instead of the primary antibody. At least 10 randomly selected microscopic fields were examined using a 10 and 40x objective. Photos were taken using a SPOT Digital camera.
Statistical analysis
All statistical analyses were performed using the Microsoft Excel data analysis program for t-test analysis or using SPSS statistical analysis program for ANOVA with the Bonferroni test. Experiments were repeated at least three times unless otherwise stated. Values were expressed as a mean ±SE.
RESULTS
Given the importance of Notch activation in determining cell fate, we examined Notch1 gene expression in two human osteoblastic prostate cancer cell lines (C4-2B and MDA PCa 2b) and compared them to brain (DU145) and lymph node (LNCaP) metastatic prostate cancer cell lines (Table 1 ). Figure   1A demonstrates that Notch1 gene expression is increased five-fold in osteoblastic (C4-2B and PCa 2b) To examine the ability of prostate cancer metastases to function similar to osteoblasts and to form mineralized bone, we cultured LNCaP, MDA PCa 2b, and C4-2B cells with and without osteogenic medium, consisting of normal culture medium, supplemented with ascorbic acid and β-glycerophosphate. Osteogenic induction induces the osteoblastic differentiation of pre-osteoblasts by increasing the activity of MAP kinase which ultimately leads to an increase in Runx2 activation and DNA binding (28) .
In addition, osteoblastic cell differentiation is also positively regulated by Notch1 (19) . Therefore, we Figure 5A and B demonstrate that osteogenic induction increases ERK phosphorylation in C4-2B cells, as in osteoblasts, without any change in the total ERK levels. Notch signaling does not seem to play a role in this activation as we show no significant difference in ERK activity when Notch signaling was inhibited for 24 hours by 1000 nM L-685,458 ( Figure 5A ). As expected, U0126 inhibited the activation of ERK in response to osteogenic induction ( Figure 5B ).
The activity of MAP kinase in osteoblasts ultimately leads to an increase in Runx2 expression and its activation/nuclear localization (30) . Furthermore, it has been reported that in papillomavirus-associated neoplasia, Notch activation plays a role in regulating proliferation and apoptosis (38) . The inhibition of γ-secretase by L-685-458 treatment had no effect on proliferation and viable cell numbers as determined by trypan blue exclusion method (data not shown). On the other hand, we were not able to inhibit ERK activation for the duration of the culture to examine its role in calcium deposition by C4-2B cells because of the cytotoxic effects of the inhibitors.
DISCUSSION
HES-1 is the best characterized member of the mammalian HES family and it is has been shown to be an important downstream target of Notch signaling (39) . HES genes encode basic Helix Loop Helix results, since we demonstrate that ERK activation is Notch-independent due to the absence of a response in ERK activation to L-685-458 treatment. We also demonstrate that Notch activation in C4-2B cells is ERK-independent since there is no change in HES-1 expression in response to U0126 treatment.
Interestingly, we did not detect any activation of ERK until cells were treated with osteogenic media.
Therefore, we believe that in prostate cancer metastases the concomitant activation of the ERK and Notch pathways while in the bone microenvironment is critical for the successful osteoblastic change of phenotype.
We, and others, have shown that osteoblastic prostate cancer metastatic cells, like osteoblasts, also express Runx2 in response to osteogenic media (10) and it has been shown that inhibition of Runx2 expression in C4-2B cells leads to loss of their mineralizing capability (10) . These findings are consistent with our results. We demonstrate here that inhibition of ERK activation, but not Notch, decreases Runx2 gene expression and nuclear protein localization. Interestingly, we also show that Runx2 gene expression Table 1 . Prostate cancer cell lines used in these studies.
TABLE 1
Cell Line Characteristics Reference
C4-2B
• Forms osteoblastic bone metastases in vivo • Derived from LNCaP cells 
DU145
• Isolated from brain metastases
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